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Conformational changes and translocation of
tissue-transglutaminase to the plasma
membranes: role in cancer cell migration
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Abstract
Background: Tissue-transglutaminase (TG2), a dual function G-protein, plays key roles in cell differentiation and
migration. In our previous studies we reported the mechanism of TG2-induced cell differentiation. In present study,
we explored the mechanism of how TG2 may be involved in cell migration.
Methods: To study the mechanism of TG2-mediated cell migration, we used neuroblastoma cells (SH-SY5Y) which
do not express TG2, neuroblastoma cells expressing exogenous TG2 (SHYTG2), and pancreatic cancer cells which
express high levels of endogenous TG2. Resveratrol, a natural compound previously shown to inhibit neuroblastoma
and pancreatic cancer in the animal models, was utilized to investigate the role of TG2 in cancer cell migration.
Immunofluorescence assays were employed to detect expression and intracellular localization of TG2, and calcium
levels in the migrating cells. Native gel electrophoresis was performed to analyze resveratrol-induced cellular
distribution and conformational states of TG2 in migrating cells. Data are presented as the mean and standard
deviation of at least 3 independent experiments. Comparisons were made among groups using one-way ANOVA
followed by Tukey-Kramer ad hoc test.
Results: TG2 containing cells (SHYTG2 and pancreatic cancer cells) exhibit increased cell migration and invasion in
collagen-coated and matrigel-coated transwell plate assays, respectively. Resveratrol (1 μM-10 μM) prevented
migration of TG2-expressing cells. During the course of migration, resveratrol increased the immunoreactivity of
TG2 without affecting the total TG2 protein level in migrating cells. In these cells, resveratrol increased calcium
levels, and depletion of intracellular calcium by a calcium chelator, BAPTA, attenuated resveratrol-enhanced TG2
immunoreactivity. In native-polyacrylamide gels, we detected an additional TG2 protein band with slower migration
in total cell lysates of resveratrol treated cells. This TG2 form is non-phosphorylated, exclusively present in plasma
membrane fractions and sensitive to intracellular Ca2+ concentration suggesting a calcium requirement in
TG2-regulated cell migration.
Conclusions: Taken together, we conclude that resveratrol induces conformational changes in TG2, and that
Ca2+-mediated TG2 association with the plasma membrane is responsible for the inhibitory effects of resveratrol
on cell migration.
Keywords: Cell migration, Invasion, Neuroblastoma, Resveratrol, Tissue-transglutaminase
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Background
Tissue-transglutaminase (TG2) possesses Ca2+-dependent
transamidation activity by which it catalyzes the cross-
linking of proteins via the formation of proteolytically re-
sistant ε-(γ-glutamyl) lysine isopeptide bonds between the
glutamine residue of one protein and the lysine residue of
another protein, polyamine, or monoamine [1-3]. In
addition, TG2 acts as a G-protein with GTP-binding and
hydrolyzing activity which regulates transamidation func-
tion [4,5]. In the extracellular matrix (ECM), TG2 medi-
ates cell-ECM interactions through fibronectin and
integrins [6,7] and promotes cell attachment, migration
and invasion [8,9]. When TG2 is present at the plasma
membrane, it acts as a G-protein and participates in α1-
adrenergic signaling [4].
Depending upon the cell type and cellular distribution,
TG2 is physiologically involved in cell differentiation,
cell death, migration, invasion or survival [10,11]. The
increased cellular level of TG2 contributes to the devel-
opment of drug resistance and metastatic phenotype in
several cancer cell types such as that of pancreatic can-
cer [12], ovarian cancer cells [13,14], breast cancer [15],
glioblastoma and malignant melanoma [16]. Studies car-
ried out in an ovarian cancer xenograft model [17] and
in mammary epithelial cell lines [18] indicated a direct
correlation of TG2 with cancer cell invasion and tumor
metastasis. The suppression of TG2 expression, using a
TG2 inhibitor or siRNA, induces apoptosis in pancreatic
cancer tissue [19]. Moreover, increased level of TG2 by
epidermal growth factor (EGF) treatment protects cancer
cells from doxorubicin-induced apoptosis highlighting the
role of TG2 in cancer cell survival [20]. In our previous
studies we reported that TG2 plays a key role in retinoic
acid-induced cell differentiation [21,22]. However, the
mechanism underlying tissue-transglutaminase mediated
cell migration is not well known.
In the present study, using neuroblastoma wild type
SH-SY5Y cells, SH-SY5Y cells with overexpressing TG2
(SHYTG2) and pancreatic cancer cells (which express
higher basal TG2), we have demonstrated that TG2 pro-
motes both cell migration and invasion. To address the
molecular mechanism(s) involved in TG2-mediated can-
cer cell migration, we used a polyphenolic compound, res-
veratrol (3,5,4’-trihydroxystilbene) which is found in red
grapes and blueberries and has shown promising results
in the treatment of neuroblastoma and other cancers.
However, high concentrations of resveratrol were used in
these studies and were focused on resveratrol-induced cell
death and the underlying signaling mechanisms [23-27].
The goal of our study was to determine if resveratrol at
lower concentrations affects cancer cell migration and in-
vasion and whether it targets TG2 to modify endpoints.
Our data suggest that resveratrol reduces the migra-
tion of TG2-containing cells (SHYTG2 and pancreatic
cancer cells). In migratory cells, resveratrol increases
Ca2+ levels and converts TG2 into open extended form
(as detected by non-denaturing gel electrophoresis). The
conversion of TG2 is sensitive to Ca2+ levels, and the
open extended form is exclusively present in the plasma
membrane fraction of migratory SHYTG2 and pancreatic
cancer cells. Together, we show that Ca2+-mediated TG2
association to the cell membrane is responsible for the
inhibitory effects of resveratrol on cell migration.
Methods
Cell culture
Human neuroblastoma SH-SY5Y cells (ATCC, Manassas,
VA), SHYvector, SHYTG2, and SHYmutant cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
with 10% fetal bovine serum (FBS; Atlanta Biologicals,
Lawrenceville, GA). The pancreatic cancer cell lines Panc-
28 and Hs766T were maintained in RPMI medium with
10% FBS [12].
Scratch assays for cell migration
The cell mobility was determined by scratch assays [28].
Briefly, cells were grown in complete culture medium
(with 10% FBS) to a confluent monolayer (up to 90%) in
100 mm2 tissue culture dishes, and treated with 10 μM
mitomycin c (Sigma-Aldrich, St. Louis, MO) for 30 min
to inhibit cell proliferation. Cells were washed twice with
complete medium and incubated with 1 μM or 10 μM
of resveratrol (Sigma-Aldrich, St. Louis, MO). After 24 h
incubation, a wound was made by scratching the dish
uniformly with a pipette tip, washed twice with complete
culture medium, and cells were further grown in
complete culture medium in the presence of respective
concentrations of resveratrol. Cells treated with a similar
volume of dimethyl sulfoxide (DMSO) were used as con-
trol. Cell migration into the empty space was monitored
by capturing images at different time points. The dis-
tance covered by cells in the empty area was calculated
in %.
Collagen-transwell cell migration and matrigel-transwell
cell invasion assays
Cell migration studies were performed using transwell
inserts with a filter of 8 μm pore size (BD bioscience,
San Jose, CA) and coated with 10 μg/ml collagen IV
(Santa Cruz Biotechnology, Santa Cruz, CA). After 48 h
treatment with resveratrol or DMSO, cells were trypsi-
nized and 2 × 104 cells in serum-free medium with res-
veratrol were seeded into the upper chamber of the
transwell insert. Culture medium with 10% FBS was
added to the lower chamber. After 15 h incubation, cells
migrated on the lower surface of inserts were stained
with Hema3 stain (Fisher Scientific, Kalamazoo, MI),
photographed, and counted from 10 randomly selected
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fields. Cell invasion studies were performed using matrigel-
coated transwell plates (BD bioscience, San Jose, CA) fol-
lowing experimental procedure similar to collagen-
transwell migration assays.
Immunofluorescence microscopy
Scratch assays as described above were performed in
Lab-TekII chamber slides (Fisher Scientific, Pittsburgh,
PA). Cells were fixed with 4% paraformaldehyde in phos-
phate buffered saline (PBS), permeabilized with 0.2%
Triton X-100/PBS, blocked with 5% bovine serum albu-
min (BSA) in PBS with 0.1% Tween-20 (PBST) at 4°C
for overnight, and incubated with monoclonal anti-TG2
antibody (Neomarker/Thermoscientific, Rockford, IL) in
5% BSA/PBST at 4°C for overnight. Primary antibodies
were detected with rhodamine-labeled anti-mouse IgG
antibody (2 h incubation at room temperature). After
washing with PBST, slides were mounted with Vectashield
mounting media (Vector Laboratories, Burlingame, CA),
and visualized under Nikon E-600 fluorescence micro-
scope [29]. Nuclei were counterstained with DAPI
(Sigma). TG2 on the outer surface of plasma membrane
was detected as described by Akimov and Belkin [8].
Briefly, cells grown in chamber slides were incubated with
anti-TG2 antibody (10 μg/ml in PBS) at 37°C for 4 h, fixed
with 4% paraformaldehyde/PBS for 20 min, and blocked
with 5% BSA/PBS for 2 h. Primary antibody (anti-TG2)
was detected by rhodamine-conjugated goat anti-mouse
IgG antibody under Nikon E-600 fluorescence microscope.
Isolation of total cell proteins, plasma membrane proteins
and Western blotting
After treatments in scratch assays, cells near (~1 mm
from the scratch) and away from the scratch were col-
lected separately. For total cell extract preparation, cells
were lysed with cell lysis buffer (Cell Signaling Technol-
ogy, Danvers, MA), incubated for 30 min at 4°C, centri-
fuged at 12,000 g for 10 min at 4°C and supernatant
(containing total cell proteins) was collected. Cytoplas-
mic and plasma membrane protein enriched fractions
were prepared using plasma membrane protein extrac-
tion kit (BioVision Inc, Milpitas, CA). Extracted proteins
were stored at −80°C, and protein quantitation was per-
formed by bicinconinic acid method (Pierce/Thermo-
Scientific, Rockford, IL). Proteins were separated by SDS-
polyacrylamide gel electrophoresis followed by Western
blots as described previously [30]. The primary antibodies
used were: TG2 (Neomarker/Thermoscientific), glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH), Na+/K+-
ATPase (Santa Cruz Biotechnology, Santa Cruz, CA), and
p-tyrosine (Millipore, Billerica, MA).
For total native protein isolation, cells were lysed in
lysis buffer (0.1 M Tris, pH 7.4, 0.05% Triton X-100,
0.5 mM PMSF, 10 μg/ml leupeptin, 10 μg/ml pepstatin,
1 mM NaF, 1 mM Na3VO4, 1 mM β − glycerophosphate,
and 2.5 mM sodium pyrophosphate) for 1 h on ice. After
centrifugation at 12,000 g for 15 min at 4°C, the super-
natant (containing native proteins) was collected, and
quickly stored at −80°C until use. For non-denaturing
gel electrophoresis, equal amount of proteins (5 μg) were
mixed with 5× loading buffer (without reducing agents
and SDS), and separated in 12% native gel (without SDS)
in running buffer (25 mM Tris, 192 mM glycine) for
12 h at 4°C. Separated proteins were transferred to
PVDF membrane and Western blots were performed as
described above.
Transglutaminase activity and GTP-binding assays
Extracted proteins (5 μg) from total cells and cytoplasmic
or membrane fractions were used to detect the transgluta-
minase activity of TG2 using tissue-transglutaminase col-
orimetric microassay kit (Covalab, Villeurbanne, France).
The assay uses biotinylated T26 peptide (Biotin-pepT26)
and spermine as substrates. In the presence of TG2,
spermine is incorporated into the γ carboxamide of the
glutaminyl residue of the biotin-pepT26 to form a biotin-
pepT26-γ-glutamyl spermine. In brief, protein samples
with assay mixture containing Biotin-pepT26 were incu-
bated in spermine-coated 96-well microtiter plate, and the
incorporation of spermine to Biotin-pepT26 was detected
by sptreptavidin-avidine labelled peroxidase system. The
color intensity as an indicator of TG2 activity was mea-
sured at 450 nm in a Spectramax spectrophotometer (Mo-
lecular Devices, Sunnyvale, CA). Photoaffinity labeling of
GTP binding proteins with [α32P]-GTP was performed as
described previously [31]. Briefly, 5 μg protein samples (in
20 μl) in 96 well-plates were incubated with 20 μl of reac-
tion buffer (50 mM Hepes, pH 8.0, 1 mM EDTA, pH 8.0,
1 mM DTT, 10% glycerol) containing 2 μCi of [α32P]-GTP
for 30 min at room temperature. Reactions were irradiated
with UV-light (254 nm) for 15 min on ice. After irradi-
ation, samples were mixed with 5× SDS loading buffer,
boiled for 5 min and separated on SDS-polyacrylamide
gels. Protein samples were transferred to PVDF mem-
brane and the membranes were exposed to x-ray film.
Similar membranes were used for Western blot and
probed with anti-TG2 antibody.
Detection of Ca2+ levels by fluorescence microscopy
The level of Ca2+ in cells was determined by fluorescence
microscopy using a membrane permeable Ca2+ indicator
dye, Fluo4-AM (Molecular Probes, Grand Island, NY).
Briefly, after treatment with resveratrol in scratch assays
in Lab-TekII chamber slides, cells were incubated with
Tyrode’s solution (20 mM Hepes, pH 7.4, 130 mM NaCl,
4.7 mM KCl, 1 mM MgSO4, 1.2 mM KH2PO4, 5 mM glu-
cose) containing 10 μM of Fluo4-AM dye and 0.1% pluro-
nic F-127 (Molecular Probes) for 1 h at 37°C in a 5% CO2
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incubator. After washing twice with Tyrode’s solution,
cells were further incubated for 30 min at room
temperature in the dark for de-esterification of dye. Slides
were mounted in Vectashield mounting media (Vector
Laboratories), and were visualized under fluorescence
microscope. Fluorescence intensity in cells present near
the scratch was quantified using Image-Pro Plus software
and plotted.
Data analyses
Data are presented as the mean and standard deviation of
at least 3 independent experiments. Comparisons were
made among groups using one-way ANOVA followed by
Tukey-Kramer ad hoc test (GraphPad software, La Jolla,
CA). A p-value < 0.05 was considered significant.
Results
TG2 enhances the migration and invasion of cancer cells
which is inhibited by resveratrol
We first evaluated the role of TG2 in migration of SH-
SY5Y neuroblastoma cells by scratch assays and by
collagen-transwell plate assays. Since the basal expres-
sion level of TG2 is very low in SH-SY5Y cells (nearly
undetectable by Western blot, as shown in Figure 1A),
we also used SH-SY5Y cells stably overexpressing TG2
protein (SHYTG2) [32]. SH-SY5Y cells transfected with
only the backbone plasmid (SHYvector) were used as a
control. Scratch assays in Figure 1A showed that 48 h
after scratch, approximately 86% of the empty area of
the original scratch was covered by SHYTG2 (Figure 1Aj)
in comparison to < 50% migration by SHYvector (Figure 1Ad
and Figure 1B). Similarly, compared to SHYvector cells,
SHYTG2 cells exhibited more than a two-fold higher mi-
gration in collagen-transwell migration assays (Figure 1Ca
and d and Figure 1D), and invasion through matrigel-
coated transwell inserts (Figure 1Ea and d and Figure 1F).
These results indicate that TG2 is one of the components
required for cell mobility.
To detect whether the transglutaminase activity of
TG2 is required for the migration, we performed scratch
assays with SH-SY5Y cells stably expressing a full length
TG2 mutant protein that lacks transamidation activity
due to the mutation at amino acid position 277 (C277S,
denoted as SHYmutant) [32]. Compared to SHYTG2 cell
migration (~86% of migration, Figure 1Aj), we observed
only 53% SHYmutant cellular migration in scratch assays
when grown in similar culture conditions (Figure 1Ap).
Also, SHYmutant cells had a lower rate of migration and
invasion pattern compared to SHYTG2 cells in collagen-
transwell (Figure 1Cd and g) and matrigel-transwell as-
says (Figure 1Ed and g), respectively.
The anticancer properties of resveratrol (res) have been
well documented [25]. To test whether TG2 plays a role in
the inhibitory effects of resveratrol on cancer cell
migration and invasion, we performed migration and inva-
sion assays in the presence of resveratrol. Exposure to res-
veratrol (1 μM or 10 μM) significantly inhibited the
migration of SHYTG2 cells in scratch assays (Figure 1Aj, k
and l and B) and in collagen-transwell assays (Figure 1Cd, e,
f, and D) as well as the invasion through the matrigel-
barrier in transwell inserts (Figure 1Ed, e, f and bar in F). In
contrast, resveratrol did not affect SHYvector and SHYmutant
cell migration (in scratch assays or through collagen-
transwell plates, Figure 1A-D) or invasion (through
matrigel-transwell inserts, Figure 1E and F).
We further verified the resveratrol-inhibited migra-
tion and invasion pattern in TG2 expressing human
pancreatic cancer cell lines Panc-28 and Hs766T [12].
After 48 h of DMSO treatment in scratch assays, Panc-
28 and Hs766T cells migrated into the empty area by
almost 89% and 85%, respectively. The addition of 1 μM
or 10 μM resveratrol significantly reduced the mobility of
all these cell lines in a dose dependent manner (Figure 1G).
Resveratrol (1 or 10 μM) also significantly reduced the
migration and invasion of Panc-28 cells in transwell-
migration and transwell-invasion assays, respectively
(Figure 1H).
Resveratrol increases the immunoreactivity of TG2 in
migratory SHYTG2 and pancreatic cancer cells
To determine whether resveratrol inhibits the migration of
SHYTG2 and pancreatic cancer cells by altering the expres-
sion and/or cellular distribution of TG2, we first performed
immuno-fluorescence studies for TG2 in scratch assays. The
immunofluorescence images in Figure 2A demonstrated
that the immunoreactivity for TG2 remains equally distrib-
uted after 48 h DMSO-treated SHYTG2 cells (Figure 2Ac).
In contrast, following 48 h resveratrol treatment (1 μM or
10 μM) a significant increase in the fluorescent signal for
TG2 (red in color and indicated by arrow) was observed in
the SHYTG2 cells present only near the scratch (Figure 2Ai
and o and B). In the case of the SHYmutant cells, the TG2 im-
munoreactivity remains unchanged in DMSO and resvera-
trol 1 μM or 10 μM treated cells (Figure 2Ae, k and q and
B). TG2 immunoreactivity was not detected in either un-
treated or resveratrol treated SHYvector cells (Figure 2Aa, g
and m and B). Similarly, 48 h incubation with 1 μM or
10 μM concentration of resveratrol increased TG2 immuno-
reactivity in Panc-28 (Figure 2Ca-f, and D) and Hs766T cells
(Figure 2Cg-l, and D) present near the scratch (as shown
by arrow).
TG2, in response to resveratrol, is not localized to
extracellular side of plasma membrane or secreted into
the medium
To test whether externalization of cytosolic TG2 was
involved in the anti-invasive effects of resveratrol, we
performed an immunofluorescence assay (to examine
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Figure 1 (See legend on next page.)
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TG2 on outer surface of plasma membrane) and ELISA
(to detect TG2 levels in culture medium). After 48 h treat-
ment with or without resveratrol in scratch assays, non-
permeabilized cells were incubated with anti-TG2 anti-
body. Our immunofluorescence results in Figure 3A and B
demonstrate that resveratrol did not alter the immunore-
activity of TG2 on the external surface of SHYTG2 cells
(Figure 3Ac, i and o), as well as on Panc-28 (Figure 3Ba-f)
and Hs766T cells (Figure 3Bg-l). Similarly, our ELISA re-
sult shows that resveratrol did not significantly alter TG2
secretion in culture medium collected from resveratrol-
treated and untreated SHYTG2 and Panc-28 cells in
scratch assays (Additional file 1: Figure S1).
Resveratrol increases the translocation of TG2 to the
plasma membranes of SHYTG2 and Panc-28 cells present
near the scratch
To test whether the cellular distribution and/or enzymatic
activity of TG2 is altered by resveratrol as it inhibits the
migration of SHYTG2 and Panc-28 cells, we subsequently
Figure 2 Immunofluorescence signal for TG2 in SH-SY5Y cells and pancreatic cancer cells. Representative immunofluorescence images
showing TG2 level (red color) in SHYvector, SHYTG2 and SHYmutant cells (A), and Panc-28, Hs766T cells (C). After treatment with resveratrol (1 or 10 μM) in
scratch assays, cells were labeled with anti-TG2 antibody. Nuclei were counter-stained with DAPI (blue) and slides were examined under fluorescence
microscope. Pictures were taken randomly from the edge of scratch and are representative of at least 3 independent experiments. Enhanced red fluorescence
(white arrows) in cells present near the scratch depicts increased immunoreactivity for TG2, and quantitated by Image-Pro Plus software and plotted.
Corresponding bar diagrams represent the fold change in fluorescence intensity (integrated optical density, IOD) (B and D). *p value < 0.05. Scale bar = 100 μm.
(See figure on previous page.)
Figure 1 Cell migration and invasion assays. (A) Representative images from the scratch assays showing the migration of SHYvector, SHYTG2, and
SHYmutant cells. Mytomycin C treated cells were preincubated with resveratrol (1 μM and 10 μM) for 24 h; a scratch was made and further incubated with
resveratrol. At 0 h and 48 h after scratch, cells were photographed. Dotted lines represent the edge of migrated cells in the scratch. Upper right panel:
Western blot for TG2 protein using 10 μg total cell extract from SHYvector, SHYTG2, SHYmutant, Panc-28, and Hs766T cells. (B) The distance covered by cells
in the original empty area was measured and plotted in %. Bars represent mean ± SD of three independent experiments. *p value < 0.05. (C-E) Images
from collagen-transwell and matrigel-transwell assays. After 48 h with or without resveratrol treatment, cells were trypsinized and seeded on collagen-
transwell (C) or matrigel-transwell inserts in the presence of resveratrol (E). After 15 h, migrated cells on the lower side of inserts were stained with
Hema-3 stain (arrow), counted from ten random fields and plotted (D and F). Bars are mean ± SD of at least three independent experiments and
*p value < 0.05. (G) Bar diagram represents the migration of Panc-28 and Hs766T cells in scratch assays in the presence of resveratrol as performed
with SH-SY5Y cells. Migrated cells into the original empty area were photographed and plotted. Bars are mean ± SD of three independent
experiments. *p value < 0.05. (H) Migration and invasion assays for Panc-28 cells were carried out as with neuroblastoma cells in transwell inserts.
Migrated/invaded cells were counted from 10 random fields and plotted. Bars are mean ± SD of three independent experiments. *p value < 0.05.
Kumar et al. BMC Cancer 2014, 14:256 Page 6 of 15
http://www.biomedcentral.com/1471-2407/14/256
determined TG2 protein level and enzymatic activity
(GTP-binding as well as transamidation) in these cells.
After 48 h in scratch assays, cells near the scratch (~1 mm
from the scratch) and away from the scratch were col-
lected separately, total cell extracts were prepared and
Western blots with anti-TG2 antibody was performed.
Western blots for TG2 in Figure 4A depicted that TG2
protein level is almost similar in total cell extracts pre-
pared from resveratrol-treated or -untreated SHYTG2 and
Panc-28 cells present near and away from the scratch.
However, Western blots in Figure 4B and C (upper panel)
demonstrated that TG2 protein band was detected in the
membrane fraction of cells present near the scratch only
in resveratrol treated SHYTG2 and Panc-28 cells, but not
in DMSO-treated cells (Figure 4B and C, lanes 4–6). Such
a TG2 band was not observed in the membrane fractions
from DMSO- or resveratrol-treated cells present away
from the scratch (Figure 4B and C, upper panel, lanes 10–
12). The cytosolic fractions isolated from close to or away
from the scratch had almost similar levels of TG2 proteins
in DMSO- and resveratrol-exposed cells (Figure 4B and C,
upper panel, lanes 1–3 and 7–9). The fractions that con-
tain TG2 protein exhibit comparable levels of GTP-
binding activity (Figure 4B and C, lower panel, lanes 1–3,
5, 6 and 7–9).
The bar diagram in Figure 4D depicted that resveratrol
exposure (1 μM or 10 μM) significantly increased the
transamidation activity (as determined by tissue trans-
glutaminase colorimetric microassay kit, Covalab) in
SHYTG2 total cell extracts prepared from the cells
present near the scratch (for res 1 μM, p < 0.005; and
for res 10 μM, p < 0.001 vs. DMSO). Such changes in
transamidation activity by resveratrol were not observed
in SHYTG2 total cell extracts prepared from the cells
present away from the scratch (Figure 4D). Resveratrol
exposure significantly increased transamidation activity
of TG2 in cytoplasmic and membrane fractions pre-
pared from SHYTG2 and Panc-28 cells present near the
scratch, but not in cells present away from the scratch
(Figure 4E and F).
Figure 3 Determination of extracellular levels of TG2 in response to resveratrol. Representative immunofluorescence images showing
extracellular TG2 level (red) in SHYvector, SHYTG2, and SHYmutant (A), and Panc-28 and Hs766T cells (B). After 48 h with or without resveratrol (1 or
10 μM) treatment in scratch assays, extracellular TG2 was detected using anti-TG2 antibody. Nuclei were stained with DAPI and visualized under
fluorescence microscopy. Pictures are representative of at least 3 independent experiments. Scale bar = 100 μm.
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Figure 4 Cellular distribution and enzymatic activity of TG2 in response to resveratrol. (A) Representative Western blots showing TG2
protein level in total cell extracts prepared from SHYTG2 and Panc-28 cells. After 48 h treatment in scratch assays, cells near the scratch and away
from the scratch were collected separately, and total protein extracts were prepared. Equal amount of proteins were separated on SDS-polyacrylamide
gels and Western blots for TG2 were performed. Blots were reprobed with β-actin to indicate loading. (B and C) GTP-binding and Western blots for
TG2 in cytoplasmic and membrane protein fractions prepared from SHYTG2 (B) and Panc-28 cells (C). GTP-binding activity of TG2 was performed by
UV-irradiating equal amount of proteins (5 μg) in the presence of [α32P]-GTP. UV-irradiated samples were separated by SDS-PAGE, transferred to PVDF
membrane and exposed to x-ray films. Similar blots were probed with anti-TG2 antibody for Western blotting. Antibodies against Na+/K+-ATPase and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as plasma membrane and cytoplasmic protein markers, respectively. (D, E and F) Bar
diagrams representing transamidation activity of TG2 in SHYTG2 and Panc-28 cells. After treatments in scratch assays, total cell lysate of SHYTG2 (D), and
cytoplasmic and membrane protein fractions of SHYTG2 and Panc-28 cells (E and F) prepared from cells present near and away from scratch, and
transamidation activity was measured by colorimetric assay at 450 nm. Experiments were repeated at least three times. *p < 0.05.
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Resveratrol induces conversion of compact TG2 into its
open slow mobility form in cells present near the scratch
Next, we sought to determine how resveratrol increases
TG2 immunoreactivity only in SHYTG2 and pancreatic
cancer cells present near the scratch. We subsequently per-
formed Western blots with anti-TG2 antibody under non-
denaturing conditions. The representative Western blots in
Figure 5A depict that in addition to the major TG2 protein
band (~87 kDa) another protein band of slower mobility
(~95 kDa) was detected by anti-TG2 antibody in native
protein samples from resveratrol-treated SHYTG2 and
Panc-28 cells present near the scratch (Figure 5A, upper
and middle panel, lanes 2 and 3), but not in DMSO-treated
cells (Figure 5A, lane 1). However, the slower mobility
form of TG2 was not detected in DMSO- or resveratrol-
treated SHYTG2 and Panc-28 cells present away from the
scratch (Figure 5A, lanes 4–6). Despite the appearance of
slower mobility TG2 form, we did not detect any change
in the level of higher mobility TG2 form. In SHYmutant cells
only one TG2 band of higher mobility (~87 kDa) was de-
tected in control and treatment groups (Figure 5A, lower
panel, lanes 1–6).
Since resveratrol induces translocation of TG2 to the
plasma membranes (Figure 4B and C); we further evaluated
the forms of TG2 in membrane fractions. The representa-
tive Western blots for TG2 in non-denaturing conditions
demonstrated that TG2 protein band with slower migration
was only detected in the membrane fractions prepared
from resveratrol-treated SHYTG2 and Panc-28 cells present
near the scratch (Figure 5B, upper two panels, lanes 4–6).
A TG2 band of similar mobility was also present in the
cytoplasmic fractions prepared from resveratrol-treated
cells present near the scratch (Figure 5B, lanes 2 and 3).
However, the TG2 protein band with higher mobility was
not present in resveratrol-treated membrane protein frac-
tions, but present in the cytoplasmic fraction from
DMSO- and resveratrol-treated samples (Figure 5B, lanes
1–6). These data indicated that a resveratrol-induced
slower mobility form of TG2 exists in migratory SHYTG2
and Panc-28 cells, and this is the exclusive TG2 form
present in the plasma membrane of migratory cells.
Further we checked post-translational modification,
phosphorylation, of TG2 [33] in native total cellular pro-
teins from SHYTG2 and Panc-28 cells present near and
away from the scratch, followed by Western blots under
non-denaturing conditions using anti-tyrosine antibody.
Blots in Figure 5C depict that the anti-tyrosine antibody
detects only a single protein band in both resveratrol-
Figure 5 Detection of TG2 protein under non-denaturing conditions. (A) Representative Western blots for TG2 in total cellular proteins
isolated from resveratrol-treated SHYTG2, SHYmutant and Panc-28 cells present near and away from the scratch. Equal amount of proteins were
separated on non-denaturing conditions and Western blots were done with anti-TG2 antibody. In addition to the major TG2 band, another TG2
protein band with lower migration was detected in resveratrol-treated SHYTG2, and Panc-28 cells present near the scratch. (B) Representative
Western blots for TG2 with cytoplasmic and membrane protein fractions prepared from DMSO- or resveratrol-treated SHYTG2, and Panc-28 cells
present near the scratch. Under non-denaturing conditions, TG2 protein band with slower migration was present in both cytoplasmic and
membrane protein fractions prepared from resveratrol-treated (1 and 10 μM) cells. (C and D) Western blots using anti-tyrosine antibody to detect
phosphorylation state of TG2 in total cell extract (C) and cytoplasmic and membrane protein fractions (D). Native proteins (100 μg) isolated from
resveratrol or DMSO treated SHYTG2 and Panc-28 cells present near the scratch, separated on non-denaturing gels followed by Western blot with
anti-phosphotyrosine (p-tyrosine). The bottom panel (D) represents the Western blot for TG2 in SHYTG2 cells.
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treated and untreated native protein samples that corre-
sponds to the TG2 protein of the higher mobility form
(lanes 2 and 3). Also, irrespective of resveratrol treat-
ment, anti-tyrosine antibody detects only a single band
in native proteins from cytoplasmic fractions, but not in
plasma membrane fractions from SHYTG2 and Panc-28
cells present near the scratch (Figure 5D, upper two
panels). However, we did not observe serine phosphoryl-
ation in these conditions (data not shown). This indi-
cates that the higher mobility form of TG2 is the
phosphorylated form, and the slower mobility form of
TG2, which appears in the presence of resveratrol, is
a non-phosphorylated form. This also suggests that
resveratrol-induced dephosphorylation of the higher
mobility form of TG2 may be involved in the conversion
of the compact higher mobility form into slower mobility
open structure TG2 form.
Resveratrol increases intracellular Ca2+ levels in cells
present near the scratch
Since intracellular Ca2+ levels determine TG2 conform-
ational state [34], we hypothesize that the slower migra-
tory form of TG2 may result from resveratrol-induced
changes in intracellular calcium concentrations [35]. To
test this possibility, we first performed immunofluores-
cence studies using a membrane permeable Ca2+ indica-
tor dye, Fluo4-AM, in scratch assays. The fluorescence
intensity in cells near the scratch was quantified as inte-
grated optical density (IOD) by Image-Pro Plus software
and plotted (Figure 6A and B). We found that resvera-
trol (1 μM or 10 μM for 48 h) significantly increased
Ca2+ fluorescence intensities in SHYTG2 cells present
near the scratch (Figure 6Af, g and h). In our experi-
ments, we observed that along with migrating cells,
some cells away from the scratch also exhibited
Figure 6 Changes in intracellular Ca2+ levels in response to resveratrol. (A) Representative fluorescence images showing the level of
intracellular Ca2+ in SHYvector and SHYTG2 cells. After 48 h resveratrol treatment in scratch assays, cells were labeled with Ca
2+-indicator dye,
Fluo4-AM, for 1 h, and examined under fluorescence microscope using FITC filter. Cells treated with resveratrol were also treated with cell
permeable Ca2+ chelator, BAPTA-AM (10 μM) to chelate intracellular Ca2+ in cells. Scale bar = 100 μm. Fluorescence intensity in cells present near
the scratch was measured using Image-Pro Plus software and plotted as fold change in IOD (B). (C) Representative immunofluorescence images
for TG2 in scratch assays. SHYTG2 cells were grown in chamber slides and scratch assays were performed in presence of Ca
2+ chelator, BAPTA-AM
(10 μM), alone or in combination with resveratrol (1 or 10 μM). After 48 h treatments, cells were labeled with anti-TG2 antibody (red) and images
were taken randomly from the edge of the scratch using fluorescence microscope equipped with rhodamine filter. Enhanced red intensity in cells
present near the scratch (white arrows) depicts increased immunoreactivity for TG2 that was attenuated in presence of Ca2+-chelator, BAPTA-AM.
Scale bar = 100 μm. Fluorescence intensity in cells present near the scratch was measured using Image-Pro Plus software and plotted as fold
change in IOD (D). (E) Representative Western blots for TG2 in presence of a Ca2+-chelator, BAPTA-AM, showing that resveratrol-induced slower
mobility TG2 form is sensitive to Ca2+ levels. Native proteins isolated from resveratrol treated SHYTG2 and Panc-28 cells in the presence or absence
of BAPTA-AM (10 μM) from near the scratch were isolated, separated under non-denaturing conditions, and blotted with anti-TG2 antibody. The
experiments were repeated three times.
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increased calcium fluorescence. However, the response
was more significant in the cells near the scratch.
Changes in the cytoplasmic calcium levels are known to
be transient and all the cells do not fluoresce at the same
time. Therefore we did not get synchronized calcium la-
beling. The effect on the cells away from the scratch
may be due to the secondary response of the cells near
to scratch, also shown in some previous studies [36,37].
Similar increase in fluorescence intensity of Ca2+ was
not observed when SHYTG2 cells were incubated with a
Ca2+-chelator, BAPTA-AM (10 μM), in the presence of ei-
ther concentration of resveratrol (1 or 10 μM) (Figure 6Ai
and j). In contrast to SHYTG2 cells, we did not observe
such resveratrol-induced increased Ca2+ fluorescence in
SHYvector cells (Figure 6Aa-e).
The increased levels of Ca2+ in resveratrol-treated migra-
tory SHYTG2 cells prompted us to test whether changes in
intracellular Ca2+ level are responsible for the increased TG2
immunoreactivity in resveratrol-treated SHYTG2 cells (as
seen in Figure 2Ai and o). We further checked the immuno-
fluorescence signal for TG2 in the presence of a Ca2+-chela-
tor, BAPTA-AM (10 μM), in combination with resveratrol (1
or 10 μM, 48 h) in scratch assays. Our immunofluorescence
data demonstrated that BAPTA-AM significantly attenuated
the resveratrol-induced immunoreactivity of TG2 (red color,
shown by arrow) and was similar to control-level in migra-
tory cells (Figure 6C and D). To further confirm the Ca2+-in-
duced changes in TG2 protein, we performed Western blots
for TG2 under non-denaturing conditions with native pro-
teins isolated from BAPTA-AM (10 μM) and resveratrol (1
or 10 μM, 48 h) treated SHYTG2 cells present near the
scratch. The Western blot for TG2 in Figure 6E demon-
strated that presence of BAPTA-AM reduces the intensity of
the slower mobility form of TG2 in resveratrol-treated cells
(compare lane 2, 3 and 5, 6). These results indicated the
slower migratory form of TG2 which appears in the presence
of resveratrol is sensitive to Ca2+ ions, and this form of TG2
may be responsible for the higher immunoreactivity of TG2
in cells present near the scratch.
Discussion
The role of TG2 in cancer cell metastasis and drug resist-
ance is well documented [11], however, its precise mo-
lecular mechanism in migration and invasion is not fully
understood. Here we report that TG2 promotes migration
and invasion of SH-SY5Y neuroblastoma cells. In contrast,
we have previously shown that retinoic acid-induced TG2
promotes differentiation of SH-SY5Y cells [21]. In order to
understand the opposite behavior of TG2 on cell migra-
tion and differentiation, we used a natural compound, res-
veratrol. Various in vivo studies in cancer models
including neuroblastoma confirms the anticancer proper-
ties of resveratrol [24,25], however, in vitro studies have
needed higher concentrations (>100 μM) of resveratrol to
induce apoptosis in cancer cells. Moreover, such concen-
trations are not achievable in vivo. Hence we use physiolo-
gically relevant concentrations of resveratrol (1 μM and
10 μM) in our studies to assess its effects in cancer cells.
Our experiments showed that resveratrol even at 1 μM
concentration significantly inhibited migration/invasion of
TG2 containing cells (SHYTG2 and pancreatic cancer cells)
(Figure 1A-H). The observed inhibitory effects of resvera-
trol on migration was not due to the lower viability of
cells, since the number of viable cells following DMSO
and resveratrol treatment (1 μM or 10 μM) were almost
similar in cell viability assays carried out by trypan-blue
exclusion method (Additional file 1: Figure S2). We also
observed that resveratrol significantly increased the TG2
immunoreactivity in migratory SHYTG2 and pancreatic
cancer cells (Figure 2) without affecting TG2 protein level
(Figure 4A). These results prompted us to investigate how
resveratrol increases TG2 immunoreactivity without chan-
ging the protein levels in cells. The Western blots under
non-denaturing conditions detects an additional TG2 pro-
tein band of slower mobility in total native proteins from
resveratrol-treated SHYTG2 and Panc-28 cells present near
the scratch (Figure 5A, lanes 2 and 3). Although both cel-
lular fractions (cytoplasmic and plasma membrane) ex-
hibit the slower mobility TG2 band, the membrane
fractions exclusively has this TG2 form in resveratrol-
treated SHYTG2 and Panc-28 cells present near the scratch
(Figure 5B, lanes 2, 3, 5 and 6). The slow mobility band
may be the open structure form of TG2 and the higher
mobility band may be compact form of TG2, also visual-
ized by others using native polyacrylamide gel electro-
phoresis [5,34,38].
Furthermore, we also observed a significant increase in
fluorescence levels of Ca2+ in response to resveratrol in mi-
gratory SHYTG2 cells (Figure 6Ag and h). The reduced im-
munoreactivity of TG2 by depleting the intracellular Ca2+
with BAPTA-AM in resveratrol-treated SHYTG2 migrating
cells (Figure 6Cb-e) correlate with the Ca2+ dependent
changes in TG2 immunoreactivity. The observation that
BAPTA-AM reduced the level of the slower mobility form
of TG2 in resveratrol treated cells (Figure 6E, lanes 5 and 6)
further support the requirement of Ca2+ ions in the struc-
tural modification of TG2. Resveratrol induced calcium re-
lease is supported by recent studies in myotubes and
chromaffin cells [35,37]. Previous reports suggest the exist-
ence of two forms of TG2 depending on the Ca2+ ion con-
centrations in cells with a compact closed form at low Ca2+
concentration and an open extended form at higher Ca2+
concentration [34,39-44]. Hence the observed resveratrol-
induced increased Ca2+ levels (Figure 6) sensitize TG2 which
in turn converts from the compact form into the open ex-
tended structure (slow mobility form) in the cytoplasm, and
this extended slow mobility form mobilizes to the plasma
membrane. These observations suggest that the increased
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immunoreactivity of TG2 in resveratrol-treated migratory
SHYTG2 and pancreatic cancer cells is due to greater antigen
accessibility of the anti-TG2 antibody to the Ca2+-sensitized
open low migratory form of TG2. This also explains the re-
duced levels of TG2 immunoreactivity in SHYmutant cells
(Figure 2) even in presence of similar levels of total TG2
protein as in SHYTG2 cells. Resveratrol-induced increased
Ca2+ levels might fail to convert mutated TG2 into the open
form, reducing antigen access of the anti-TG2 antibody in
SHYmutant cells.
Absence of the slow molecular form of TG2 after incu-
bation of native total SHYTG2 proteins with resveratrol (1
or 10 μM) alone or in combination with Ca2+ in an in vitro
cell-free system (Additional file 1: Figure S3) suggest that
the conversion of closed to open structure form of TG2 is
not due to a direct interaction between resveratrol and
TG2, and that other factors might also be involved in
resveratrol-induced TG2 conversion. We also tested the
possible interaction between TG2 and resveratrol by com-
putational modeling using different approaches. The
COACH server and TM-ALIGN analysis failed to predict
the significant interaction, however, another program BSP-
SLIM (for low-resolution ligand-protein docking) showed
some docking positions on TG2, but it was difficult to
evaluate if they indeed interact (Additional file 1: Figure
S4a and S4b). Thus the cell-free system and bioinformatics
approaches concluded that resveratrol did not interact sig-
nificantly with TG2. Our observation that the slower mo-
bility TG2 form is non-phosphorylated and the higher
mobility form is phosphorylated (Figure 5C) suggests that
resveratrol induces dephosphorylation of the slower mobil-
ity TG2 form which travels from cytoplasm to plasma
membrane. How shuttling of the Ca2+-sensitive open slow
mobility dephosphorylated TG2 form to cytoplasmic side
of plasma membrane occurs is not clear. A recent study re-
vealed that a heat shock protein (Hsp70) mediates TG2
transport to the plasma membrane [45]. Our results that
the open structure slow mobility TG2 band was present in
both cytoplasmic and membrane fractions, and the higher
mobility form was present only in cytoplasmic fractions
(not in membrane fractions) in SHYTG2 and Panc-28 cells
(Figure 5B) suggests that a chaperone-like activity of
Hsp70 might help in Ca2+- induced TG2 conversion, and
interaction of Hsp-70 to the open slow mobility TG2 form
might facilitate the transport of this form of TG2 from
cytoplasm to plasma membrane. Previous studies indicate
that acetylation [46] and ubiquitination of TG2 [47] inhibit
its transamidation activity and degrade the protein into
smaller fragments. In our studies increased transamidation
activity by resveratrol and absence of smaller proteolytic
fragments of TG2 suggest that resveratrol does not induce
the acetylation and ubiquitination of TG2.
In response to various stimuli, TG2 is either transported
to the cytoplasmic or extra-cellular side of plasma
membrane [48]. On the cytoplasmic side of the plasma
membrane, TG2 activates phospholipase C (PLC) and
RhoA-ROCK-2 signaling pathways [21,22,31], while on the
cell surface, TG2 acts as a co-receptor for integrins to pro-
mote cell attachments [49]. TG2 is known to positively
regulate the expression and activity of metalloproteinases
(MMPs)-2 and −9 in cancer cells [10,50]. MMPs are a fam-
ily of secreted proteins known to promote cancer cell mi-
gration through acting in extracellular environment [51].
In our scratch assays with SHYTG2 and Panc-28 cells, res-
veratrol at 1 μM or 10 μM concentrations did not affect
TG2 localization to the extracellular membrane surface
(Figure 3A and B) or its secretion into culture medium
(ELISA, Additional file 1: Figure S1). Also we did not
observe any effects on enzymatic activity of matrix metal-
loproteinases (MMPs)-2 and −9 in culture medium col-
lected after resveratrol (1 or 10 μM) treatments in scratch
assays (as revealed by gelatin zymography, Additional file
1: Figure S5) suggesting that intracellular (not extracellu-
lar) TG2-mediated signaling events are involved in the in-
hibitory effects of resveratrol in cell migration. Incubation
with Sirtinol (an inhibitor of Sirt-1, a well-known substrate
of resveratrol) did not attenuate the resveratrol-effects on
migration of SHYTG2 and Panc-28 cells suggesting that
the observed inhibition in cell migration by resveratrol is
Sirt1-independent (Additional file 1: Figure S6) [52].
By demonstrating that resveratrol induces TG2 transloca-
tion to the plasma membrane, and increases intracellular
Ca2+ levels, we propose a putative model which explains the
underlying mechanism of resveratrol effects on TG2-
mediated cell migration (Figure 7). Under normal condi-
tions, cytoplasmic TG2 remains in its phosphorylated com-
pact form and induces cell migration and invasion. Its GTP-
binding function plays a major role in mediating these
Figure 7 Putative model explaining the underlying mechanism
of resveratrol effects on TG2-mediated cell migration.
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effects and requires low intracellular calcium concentrations.
Following resveratrol exposure increased intracellular Ca2+
levels converts closed TG2 form into the open extended
form which in turn, probably with the help of Hsp70 pro-
tein, translocates to the cytoplasmic side of plasma mem-
branes. On the plasma membrane, TG2 activates the PLC
signaling pathway [31]. Activation of PLCδ pathways further
amplify the Ca2+ levels in the cytoplasm by releasing Ca2+
from intracellular organelles, which in turn increases the
transamidation activity of TG2 for the prevention of cell
migration/invasion. The observations that transamidation
activity of TG2 is required for cell migration is supported
by less mobility of transamidation-defective SH-SY5Y cells
(SHYmutant) in scratch assays (Figure 1A), and the reduced
migration of SHYTG2 cells and Panc-28 cells in the pres-
ence of a TG2 transamidation inhibitor, monodensylcade-
varine (Additional file 1: Figure S7). A recent report
demonstrating the role of a Ca2+-binding protein, S100A4,
in TG2-mediated migration further supports our observa-
tions of a Ca2+ requirement for TG2-mediated cancer cell
migration [53].
Conclusions
Together, the present study indicates that TG2 is one of the
proteins involved in cancer cells migration/invasion, and
supports its use as a therapeutic target in cancer prevention.
Although higher concentrations of resveratrol (~100 μM)
induces cell death in cancer cells [24], the current study sug-
gest that lower physiologically relevant dose of resveratrol
(~1 μM) prevent the migration and invasion of cancer cells
from the primary site. Resveratrol has shown promising re-
sults for the treatment of many diseases using animal
models [27] and recently findings have been extended to
humans. For example, in a recent clinical trial, 30 days of
resveratrol treatment (150 mg/day) induced beneficial meta-
bolic changes in obese humans [54]. Rapid metabolism and
poor bioavailability is generally thought to be a limiting fac-
tor in the use of resveratrol as a therapeutic agent in transla-
tional medicine. However, recent studies show that
resveratrol sulfate, a metabolite of resveratrol is converted
back into resveratrol inside the cells and the effective con-
centration of resveratrol inside the cells may be higher
[55]. Since retinoic acid treatment increases TG2 protein
level and resveratrol inhibits the migration of TG2-
expressing cells, this study also proposes the use of resver-
atrol with retinoic acid for the treatment of neuroblatoma.
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